Sarepta Therap

SRPT.US traded higher in the regular session, closing at $19.105 as of 10:00 AM ET, up 4.97% from the previous close of $18.200. The intraday range was $19.105 high and $18.030 low, forming a bounce-back pattern after an initial dip. Pre-market trading was steady between $18.200 and $18.480. The catalyst was the FDA's acceptance of supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, with a PDUFA date set for February 28, 2027, reducing regulatory uncertainty for key pipeline products. The stock is still 24.55% below its 52-week high of $25.32 but 83.44% above the 52-week low of $10.415, and has reclaimed both the 20-day MA ($16.604) and 60-day MA ($18.645), indicating a short-term technical recovery. However, Q1 revenue fell 1.89% YoY to $730.8 million, dragged by lower ELEVIDYS sales, which remains a headwind.